STAT

10/10/2025

This is the web edition of D.C. Diagnosis, STAT's twice weekly newsletter about the politics and policy of health and medicine.

This is the web edition of D.C. Diagnosis, STAT's twice weekly newsletter about the politics and policy of health and medicine.

10/10/2025

And other health news stories from today's Morning Rounds newsletter.

And other health news stories from today's Morning Rounds newsletter.

10/09/2025

A key Democrat is asking top Medicare Advantage insurers about how they use artificial intelligence in decisions about medical care and coverage.

A key Democrat is asking top Medicare Advantage insurers about how they use artificial intelligence in decisions about medical care and coverage.

10/09/2025

For more than a decade, no other city came close to matching Boston as the undisputed capital of the world’s life sciences industry. That could change.

For more than a decade, no other city came close to matching Boston as the undisputed capital of the world’s life sciences industry. That could change.

10/09/2025

The Trump administration is escalating its efforts to weaken a tech industry-funded group seeking to help shape the nation’s use of AI in health care.

The Trump administration is escalating its efforts to weaken a tech industry-funded group seeking to help shape the nation’s use of AI in health care.

10/09/2025

Is biotech back? And how did a math error cost AstraZeneca a rare disease candidate? All that and more on the new episode of "The Readout LOUD."

Is biotech back? And how did a math error cost AstraZeneca a rare disease candidate? All that and more on the new episode of "The Readout LOUD."

10/09/2025

And more biotech news stories, brought to you by The Readout.

And more biotech news stories, brought to you by The Readout.

10/09/2025

In today's Pharmalittle roundup, we're reading about Trump forgoing tariffs on generics, a monster MASH deal by Novo, and more.

In today's Pharmalittle roundup, we're reading about Trump forgoing tariffs on generics, a monster MASH deal by Novo, and more.

10/09/2025

SPONSORED: Defying expectations in an analog era, Regeneron sought to build a different type of company that could repeatedly deliver important new medicines from its own labs. Since its inception in the 1980s, that yearning to question everything has brought the world technologies that forever changed medicine, including the VelociSuite technology platform. At every innovative turn, Regeneron has chased discoveries that improve people’s lives, be it a health condition that affects the masses or one that affects just a few. Read more: https://sbs.statnews.com/driven-by-discovery/p/3

10/09/2025

Blue Cross Blue Shield of Massachusetts has offered buyouts to hundreds of employees as it seeks to cut its workforce amid soaring health care costs and steep losses.

Blue Cross Blue Shield of Massachusetts has offered buyouts to hundreds of employees as it seeks to cut its workforce amid soaring health care costs and steep losses.

10/09/2025

An upcoming decision on a rare disease drug from Biohaven Pharmaceuticals should shed light on regulatory flexibility under the current FDA leadership.

An upcoming decision on a rare disease drug from Biohaven Pharmaceuticals should shed light on regulatory flexibility under the current FDA leadership.

10/09/2025

Expedition Therapeutics, a company seeking to scour China’s booming biotech industry for enticing drug candidates, has raised $165 million for its first drug trial.

Expedition Therapeutics, a company seeking to scour China’s booming biotech industry for enticing drug candidates, has raised $165 million for its first drug trial.